Gala Treatment for Chronic Bronchitis in Canada

COPD Clinical Trial

Official title:

A Feasibility Study: A Safety Evaluation of the Gala Airway Treatment System on Patients With Chronic Bronchitis in Canada

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03385616
• Other study ID #: CS004
• Status: Completed
• Phase: N/A
• Start date: August 24, 2017
• Est. completion date: February 28, 2021

Study information

• Verified date: August 2021
• Source: Gala Therapeutics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Feasibility trial (FIH) to assess the safety and clinical utility in patients with chronic bronchitis in Canada.

Description:

The Gala Airway Treatment system is a device-based, energy delivery system that delivers high frequency short duration energy to the airway epithelium and sub-mucosal tissue layers. The energy is delivered via a proprietary catheter through the bronchoscope.

Two sessions of treatment will be delivered one month apart. The right lung is treated at the first treatment session and the left lung is treated at the second treatment session (approximately one month after the right side is treated). Treatment will be delivered by a respiratory physician (interventional pulmonologist) in a tertiary teaching hospital during a bronchoscopic procedure. The bronchoscopy will be delivered during general anaesthesia. It is anticipated that the bronchoscopic procedure will last less than 60 minutes in total. Treatment will be deemed to have been delivered following the successful treatment during the two bronchoscopies.

A third bronchoscopy will be performed three months following the second treatment session where treatment is not delivered but a cryo-biopsy will be taken from the airway sites that have been treated during the two previous bronchoscopic treatment session to evaluate the effect of the treatment on the airways producing excessive mucous.

Subjects will be required to submit to several tests during the study including two CT scans (lung), respiratory function tests, exercise testing.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: February 28, 2021
• Est. primary completion date: July 30, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Subject is diagnosed with chronic bronchitis for a minimum of two years, where chronic bronchitis is defined clinically as chronic productive cough for three months in each of two successive years in a patient in whom other causes of productive cough have been excluded.

2. Subject has GOLD Stage II chronic obstructive pulmonary disease (COPD) with a preprocedure post-bronchodilator FEV1 of greater than or equal to 30% and less than or equal to 80% of predicted within three months of enrollment.

3. Subject has an FEV1/FVC ration < 0.7.

4. Subject has been treated with Long Acting Beta Agonists (LABAs) or Long Acting Muscarinic Antagonists (LAMAs) or both for three months or more.

5. Subject has a cigarette smoking history of at least ten packs years.

6. Subject in the opinion of the site investigator is able to adhere to and undergo three bronchoscope procedures inclusive of lung biopsies and Gala treatments, and has provided a signed informed consent.

Exclusion Criteria:

1. Subject has active respiratory infection (e.g., common cold, pneumonia, MAI, tuberculosis) or COPD exacerbation within the last three months.

2. Subject has MMRC score greater than or equal to 3.

3. Subject is taking > 10 mg of prednisolone or prednisone per day.

4. Subject has an implantable cardioverter defibrillator or pacemaker.

5. Subject has a history of cardiac arrhythmia within past two years.

6. Subject has abnormal cardiac rhythm at time of procedure.

7. Subject has history of proven lung cancer in last 5 years.

8. Subject has pulmonary nodule or cavity requiring follow-up or intervention unless proven benign and not actively infected (e.g., aspergilloma).

9. Subject has prior lung surgery, such as lung transplant, LVRS, lung implant/prosthesis, metal stent, valves, coils, bullectomy, segmentectomy, or lobectomy. Pneumothorax without lung resection is acceptable. Pleural procedures without surgery are acceptable.

10. Subject has Alpha-1-Antitrypsin (AAT) deficiency.

11. Subject has documented history of asthma diagnosed with onset <30 years of age, clinically significant bronchiectasis or any other significant second lung disease.

12. Subject actively smoked (including tobacco, marijuana, e-cigarettes, vaping, etc.) within the last 6 months.

13. Subject has known airway colonization with resistant organisms including but not limited to pseudomonas, MRSA, B Cepacia, MTB, M abscessus, mucor or any significant fungus.

14. Subject has the inability to walk over 140 meters.

15. Subject has a serious medical condition, such as: uncontrolled congestive heart failure, uncontrolled angina, myocardial infarction in the past year, renal failure, liver disease, cerebrovascular accident within the past 6 months, uncontrolled diabetes, hypertension, autoimmune disease or uncontrolled gastric reflux.

16. Subject has known sensitivity to medication required to perform bronchoscopy (such as lidocaine, atropine, and benzodiazepines).

17. Subject is pregnant, nursing, or planning to get pregnant during study duration.

18. Subject has received chemotherapy within the past 6 months or is expected to receive chemotherapy during participation in this study.

19. Subject is or has been in another clinical investigational study within 6 weeks of baseline.

20. Subject on anticoagulation for cardiovascular indications and is unable to have anticoagulants (i.e., Aspirin, Plavix, Coumadin) withheld for at least seven days prior to bronchoscopy in the opinion of the Investigator.

Related Conditions & MeSH terms

• Acute Disease
• Bronchitis
• Bronchitis, Chronic
• Chronic Bronchitis
• COPD

Intervention

Device:
• Gala Airway Treatment System
The Gala Airway Treatment system is a device-based, energy delivery system that delivers energy to ablate soft tissue such as the airway epithelium and sub-mucosal tissue layers. The energy is delivered via a proprietary catheter through the bronchoscope.

Locations

Country	Name	City	State
Canada	Notre Dame Hospital at CHUM	Montreal
Canada	IUCPQ Quebec	Quebec
Canada	St. Paul's Hospital Vancouver Centre for Heart Lung Innovation	Vancouver	British Columbia

Sponsors (1)

Lead Sponsor	Collaborator
Gala Therapeutics, Inc.

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	CASA-Q	Patient reported outcome respiratory questionnaire: Cough and Sputum Assessment Questionnaire	Through end of study (12 months post-bilateral treatment)
Primary	Safety: Incidence of serious adverse events associated with the Gala Airway Treatment System through 6 months.	Incidence of serious adverse events associated with the Gala Airway Treatment System through 6 months.	6 months
Secondary	Clinical Utility - Histology	Histopathological evidence of change in mucus producing cells within the airway	3 months following bilateral treatment
Secondary	Clinical Utility - Pulmonary Function	Pulmonary function testing (PFT) utilizing Forced Expiratory Volume (FEV1)	Through end of study (12-months post-bilateral treatment)
Secondary	Quality of Life - CAT	COPD Assessment Test (CAT) questionnaire	Through end of study (12-months post-bilateral treatment)
Secondary	Quality of Life - SGRQ	St. George Respiratory Questionnaire (SGRQ)	Through end of study (12-months post-bilateral treatment)
Secondary	Acute Exacerbations	Detection of acute exacerbations (measured by clinical examination of a suitably qualified physician)	From 48 hours post procedure through end of study (12 months post-bilateral treatment)
Secondary	Non-Acute Exacerbations	Detection of non-acute exacerbations (measured by clinical examination of a suitably qualified physician)	From 48 hours post procedure through end of study (12 months post-bilateral treatment)
Secondary	Six Minute Walk Test	Change in 6MWT at 6 months compared to baseline	6 months post-bilateral treatment